Can a Small Local Centre Give Immunotherapy Safely? — The Capability Checklist

Sometimes yes, sometimes no. Size is not the test. Capability is. A small unit with a responsible oncologist, verified drug handling, trained infusion nurses, same-day bloods, steroids on the shelf and a written route to a hospital bed is safe. A large one missing those things is not.

The infusion itself is the easy part. It takes thirty minutes to an hour, it is given as day care, and most people go home the same afternoon. What immunotherapy actually demands of a centre is everything that happens between cycles — noticing an unusual symptom, testing for the right thing, starting steroids on the correct day, and having somewhere to admit you when that is not enough. Judge a centre on those nine capabilities, in this order.

Number nine matters more than families expect. If you are ever seen by a doctor who does not know you — in a district hospital, at night, in another city — the treatment record in your hand is what tells them to think of an immune side effect at all. Your Treatment Card: The Document to Carry Everywhere sets out exactly what that record should contain.

The infusion itself is usually uneventful. The risk sits in the weeks afterwards. Immune side effects can affect the gut, lungs, liver, thyroid, adrenal glands or heart, and they are easy to mistake for infection. A centre that cannot recognise them quickly, start steroids and admit you is the risk.

• The symptom is attributed to something else. Loose motions become “food poisoning”, breathlessness becomes “chest infection”, exhaustion becomes “weakness after treatment”. Antibiotics are given, steroids are not, and days pass.
• Steroids are started late, or stopped too fast. Immune-related inflammation is managed with corticosteroids on a defined schedule, tapered slowly. A short course stopped early is a common route back to the emergency room.
• Monitoring is not actually happening. Thyroid, liver and kidney changes usually appear on a blood test before they appear in the patient. If the panels are ordered irregularly, or the results are filed unread, the early warning is lost.
• There is nowhere to escalate at 2 am. An immune side effect does not respect clinic hours. Without a doctor on the phone and a hospital that will admit, the family is left improvising in a casualty department that has never heard of the drug.
• The medicine came from outside the hospital pharmacy. Counterfeit checkpoint inhibitors have been reported entering the Indian market. A cold-chain biologic bought off-bill cannot be traced, verified, or returned — and the saving is never worth it.

When the plan is settled and the local unit meets the checklist. Eligibility and the first cycles belong where the backup is fullest. Once you are tolerating treatment, later cycles can move closer to home under a written shared-care plan, with one named oncologist still answerable for the whole course.

The arrangement that makes this work has a name: shared care. It only functions if four things are true. One oncologist stays formally responsible for the course. The plan — drug, dose, interval, which bloods, which thresholds trigger a call — is written down and both teams hold a copy. The local unit knows exactly when to stop and phone rather than proceed. And you carry your own records to every visit. Without those four, “shared care” is just two teams each assuming the other is watching.

Distance is a real cost, and it is fair to plan around it. For a family travelling in from a district, a cycle is rarely just the cycle: it is transport, a day of lost earnings for whoever accompanies the patient, sometimes a night’s stay, and the same again for every review. Over a course that runs many months, that quietly becomes one of the larger numbers in the whole treatment — indicative, as of August 2026, and different for every family. Say it out loud in the consultation. A plan built without it is a plan that gets abandoned halfway. Where the barrier is affordability rather than distance, Government vs Private Immunotherapy Access in Telangana sets out what each route can and cannot do.

Ask about systems, not about people. Every question below is about what is stocked, who is on call and what is written down. No good unit minds being asked. A centre that reacts badly to a written question has answered it. Ask the same seven everywhere, so the answers can be compared.

1. 1

   Who is responsible for me?

   Ask for the name of the medical oncologist who owns the prescription and the reviews, and how often you will actually see that person.

2. 2

   Where does the medicine come from?

   Ask about procurement and the cold chain. The answer should involve the hospital pharmacy and a traceable batch record, never a suggestion that you source it yourself.

3. 3

   What is in the infusion room?

   Ask what is stocked for a reaction during the infusion and who in the room is trained to use it. This is a routine question and staff expect it.

4. 4

   Can bloods be reported the same day?

   Ask specifically about thyroid, liver and kidney panels. Monitoring you have to wait three days for is monitoring that arrives after the decision.

5. 5

   What happens on a Sunday?

   Ask who answers the phone at night, what they can authorise, and how quickly steroids can be started if you cannot reach the clinic.

6. 6

   Which hospital admits me?

   Ask for the named hospital, whether the arrangement is written, and whether it has intensive care. “We will manage” is not an escalation plan.

7. 7

   What do I take home after each cycle?

   Ask for the drug name, dose, batch and date in writing every time, plus your reports. If records are hard to get now, they will be harder later.

Two answers should stop the conversation rather than continue it: a promise about how well the treatment will work, and pressure to start today at a price that holds only today. Neither is a capability. Red Flags When a Centre Recommends Immunotherapy covers what those conversations tend to sound like.

CION does not provide CAR-T or any other cell therapy, and does not stock CAR-T product. That treatment belongs at a licensed cell-therapy centre. If it is raised as an option for you, the right next step is a referral to such a centre, not a search for a local unit willing to attempt it.

CAR-T is a different category of treatment from a checkpoint inhibitor infusion, and the capability question is not a matter of degree. It requires apheresis to collect the patient’s own cells, a licensed facility to modify and grow them, conditioning treatment before they are returned, and a team that manages cytokine release syndrome and neurological toxicity in an intensive-care setting. Very few centres in India are set up for it, and the list changes.

• What CION can do. Explain what has been proposed, what the eligibility questions usually are, and help you understand where such a referral would go.
• What CION does not do. Administer, arrange, stock or supervise CAR-T or any other cell therapy. Nothing on this page should be read as an offer of it.
• What to be wary of. Any unit offering cell therapy alongside routine day care, or any clinic offering unproven immune infusions under a similar-sounding name.

Capability is one of four questions families ask at this stage. The others are what each funding route can actually cover, what paperwork to carry between centres, and how to recognise a recommendation that does not add up. These pages take each one in turn.

• Government vs Private Immunotherapy Access in Telangana — what each route realistically covers, and where the waiting and the out-of-pocket gap actually fall.
• Your Treatment Card: The Document to Carry Everywhere — the one-page record that lets any doctor, anywhere, act correctly if something goes wrong.
• Red Flags When a Centre Recommends Immunotherapy — the warning signs in a recommendation, and the questions that surface them early.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring and escalation fit together as one pathway.

One last thing worth saying plainly: not starting immunotherapy is a legitimate option, and so is being treated somewhere other than here. If the treatment does not suit the situation, or the nearest capable centre is genuinely out of reach for your family, that belongs in the conversation with your oncologist before the first cycle — not in a decision made quietly, halfway through.

Get the Capability Question Answered in Writing

Bring your reports. We will set out the plan, the monitoring it needs and the escalation route in writing, so whichever centre you choose can be held to it.